首页> 外文期刊>Expert opinion on therapeutic targets >Regulators of G protein signalling: potential targets for treatment of allergic inflammatory diseases such as asthma.
【24h】

Regulators of G protein signalling: potential targets for treatment of allergic inflammatory diseases such as asthma.

机译:G蛋白信号的调节剂:潜在的目标,用于治疗过敏性炎症性疾病,例如哮喘。

获取原文
获取原文并翻译 | 示例
           

摘要

Asthma, a disease that affects nearly 15% of the world's population, is characterised by lung inflammation and reversible airway obstruction, which leads to wheezing and dyspnoea. Asthma is a prototype for allergic processes initiated by tissue inflammatory leukocytes, such as mast cells, whose secreted mediators recruit lymphocytes and eosinophils to the lung parenchyma. Signals transmitted through G-protein-coupled receptors (GPCRs) contribute to both the development and perpetuation of allergic processes, and pharmacological agents that block or stimulate GPCR action have been a mainstay of allergic disease therapy. Despite the widespread use of GPCR-targeted agents, little is understood about intracellular regulation of G protein pathways in immune cells. Regulators of G protein signalling (RGS proteins) enhance G protein deactivation and may contribute to the specificity and precision characteristic of GPCR signalling pathways. This review discusses the emerging functions of RGS proteins in immuneprocesses and inflammatory states such as asthma, and their potential value as therapeutic targets for the treatment of allergic disease.
机译:哮喘是一种影响全球近15%人口的疾病,其特征是肺部炎症和可逆性气道阻塞,导致喘息和呼吸困难。哮喘是由组织性炎症白细胞(例如肥大细胞)引发的过敏过程的原型,其分泌的介质将淋巴细胞和嗜酸性粒细胞募集到肺实质。通过G蛋白偶联受体(GPCR)传输的信号有助于过敏过程的发展和持久化,而阻断或刺激GPCR作用的药理学药物一直是过敏性疾病治疗的主要手段。尽管以GPCR为靶标的药物得到了广泛使用,但对免疫细胞中G蛋白途径的细胞内调节了解甚少。 G蛋白信号传导的调节剂(RGS蛋白)增强G蛋白失活,可能有助于GPCR信号通路的特异性和精确性。这篇综述讨论了RGS蛋白在免疫过程和炎症状态(例如哮喘)中的新兴功能,以及它们作为过敏性疾病治疗靶标的潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号